

A panel of single amino acid substitutions to positions p5 through p8 of the CEA peptide CAP1 were made by f-moc chemistry using pin technology (Chiron Mimotopes, Victoria, Australia). CAP1 (YLSGANLNL; SEQ ID NO:1) and CAP1-6D (YLSGADLNL; SEQ ID NO:2), greater than 96% pure, were also made by Multiple Peptide Systems (San Diego, CA). Additional peptides CAP1-7I and NCA571 were synthesized on an Applied Biosystems 432A synthesizer and were greater than 90% pure by C18 reverse-phase HPLC.

REMARKS

The Notice to Comply with Sequence Rules indicated that that the application failed to comply with the requirements of 37 C.F.R. §§1.821-1.825. In particular, the Notice indicated the peptide sequences on page 28 of the application did not have corresponding SEQ ID NOS. Accordingly, Applicants were required to submit a substitute Sequence Listing in computer readable form; and a statement that the computer readable and paper forms of the Sequence Listing were identical.

As a result of this Amendment, the paragraph at page 28, lines 27-33 to page 29, lines 0-1 was amended to include the appropriate SEQ ID NOS. In addition, a substitute Sequence Listing has been submitted to correct the information pertaining the applicants names, the pending application data, and the prior application data for the listing. The substitute Sequence Listing has been submitted in both paper and computer readable forms, and is accompanied by a statement indicating that the paper and computer readable forms are identical.

Applicants note that the peptide sequences shown on page 28 of the specification correspond to SEQ ID NO:1 and SEQ ID NO:2. Accordingly, these peptide sequences were not added as new sequences in the substitute Sequence Listing. In the event that the Examiner is of

the opinion that further discussion of the substitute Sequence Listing would be helpful, the Examiner is hereby respectfully requested to telephone Applicants' undersigned representative at (212) 415-8742 and is assured of full cooperation in an effort to advance the prosecution of the application.

It is believed that, as presently amended, the instant application fully complies with the requirements of 37 §§1.821-1.825.


AUTHORIZATION

Should any fee(s) be required by the filing of this Amendment and accompanying papers, authorization is hereby given to the Commissioner to charge the amount of any such fee(s) that is/are properly assessable in this application to Deposit Account No. 13-4500, Docket No. 2026-4266US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: November 27, 2001

By: _____


Caryn DeHoratius
Registration No. 45,881

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



APPENDIX

AMENDED PARAGRAPH WITH MARKINGS TO SHOW CHANGES MADE

Paragraph at page 28, lines 27-33 to page 29, lines 0-1:

A panel of single amino acid substitutions to positions p5 through p8 of the CEA peptide CAP1 were made by f-moc chemistry using pin technology (Chiron Mimotopes, Victoria, Australia). CAP1 (YLSGANLNL; SEQ ID NO:1) and CAP1~6D (YLSGADLNL; SEQ ID NO:2), greater than 96% pure, were also made by Multiple Peptide Systems (San Diego, CA). Additional peptides CAP1-7I and NCA571 were synthesized on an Applied Biosystems 432A synthesizer and were greater than 90% pure by C18 reverse-phase HPLC.